August 2019 - AUA Public Policy Council Update for MAS

From the Chair

I am pleased to share updates from the AUA Public Policy Council that may benefit your Section members. Our updates include information on our meeting with more than 35 state legislators and staff to discuss AUA’s state advocacy priorities. We also welcome John Fortin as the inaugural Patient Advocacy Liaison to the Public Policy Council.

State Advocacy Update: NCSL Legislative Summit 2019

This month, the AUA attended the 2019 National Conference of State Legislatures (NCSL) in Nashville, Tennessee. The AUA had a booth in the exhibit hall, where state legislators, legislative staff, and others interested in public policy could stop by to learn about the AUA and discuss state policies relating to urology.

Highlights of the conference include:

  • The AUA held discussions with more than 35 legislators and staff regarding our model legislation (while highlighting New York’s benchmark law). Specifically, AUA held conversations with the following states (but not limited to) – Alabama, Arkansas, California, Connecticut, Georgia, Hawaii, Kansas, Kentucky, Maryland, Michigan, Missouri, North Carolina, New Mexico, Ohio, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Wisconsin, and Wyoming.
  • AUA handed out 200 prostate cancer awareness pins to conference attendees.
  • AUA handed out 60 folders that included information about the AUA and advocacy efforts. 

The AUA will follow-up on discussions with legislative members and their staff from the conference. The AUA also will continue to work closely with our State Advocacy Committee to continue our development of a legislative strategy for next year.  If you have any questions, feel free to reach out to AUA’s State Advocacy Manager, Andrea Oh at AOh@AUAnet.org

Patient Advocacy Liaison to the Public Policy Council: Welcome John Fortin!

We are pleased to announce that John Fortin was selected as the inaugural Patient Advocacy Liaison (PAL) to the Public Policy Council (PPC). John is a prostate cancer survivor and advocate nominated by Prostate Cancer International. Mr. Fortin was a featured panelist at the 2019 AUA Advocacy Summit, where he shared his personal story of living with prostate cancer and discussed active surveillance and the importance of shared decision making. He received his bachelor’s degree in mathematics and economics from Tufts University and a master’s degree in actuarial science from Northeastern University. He also attended the London School of Economics. His career started as a group actuary in the insurance industry before moving into employee benefits consulting. Currently, Mr. Fortin serves as a part-time journalist for UroToday® and covers the AUA Annual Meeting as well as other clinical conferences.

As a reminder, the PAL will serve a one-year term on the Council beginning on January 1, 2020. The non-voting position is designed to provide expertise and guidance on how patients are impacted by the AUA’s advocacy initiatives. The position will provide suggestions for making AUA advocacy initiatives patient-centered and interact with patient advocacy partners to receive feedback and relay information. The liaison will work closely with the AUA’s Patient & Research Advocacy team and convey emerging advocacy issues in the patient advocacy space.

AUAPAC: Section Giving Competition Launched!

In an effort to help raise individual donations to AUAPAC, which represents the voice and broad interests of all its domestic members, the AUA has launched a friendly competition for all eligible AUA Sections. The winning section will receive formal recognition and a $5,000 “award” from the AUA. The contest will run from August 1, 2019 through the Annual Urology Advocacy Summit in March 2020.

Eligibility

Domestic members of the Mid-Atlantic, New England, Northeastern, Southeastern, North Central, South Central, and Western Sections are all eligible to participate in the contest. Please note, since the New York Section (NYAUA) only maintains a 501(c)(3) entity, it may not participate in the Section contest. Doing so could jeopardize that section’s tax status with the Internal Revenue Service. AUA members in NYAUA may give individually to AUAPAC, but those contributions cannot be tied back to the Section or ask the Section to help with solicitations.

Categories

Various giving categories will be measured during the contest, with each category winner earning a maximum 100 points for the respective Section. The Section earning the most points will be announced at the conclusion of the 2020 AUA Summit.

“Scored” categories include the following:

  • Highest individual donation
  • Highest percentage of domestic member participation
  • Section raising the most money per capita
  • Highest percentage of Section board member participation
  • Highest number of residents/fellows participation

The following insurance carriers provide national coverage.

Aetna

Aetna has made the following changes to criteria and supporting information:

  • Increased age at which prostate-specific antigen (PSA) screening is considered a medically necessary preventive service for men who are considered average-risk for prostate cancer from 40 years of age and older to 45 years of age and older,
  • Increased age at which prostate-specific antigen (PSA) screening is considered a medically necessary preventive service for men who are considered at high-risk for prostate cancer from under 40 years of age to 40 years of age and older,
  • Added note stating that routine prostate cancer screening for members 75 years of age or older is considered not medically necessary unless life expectancy is greater than or equal to 10 years.

Read the complete policy here.

Anthem Blue Cross

Anthem Blue Cross has made the following changes to their Surgical and Minimally Invasive Treatments for Benign Prostatic Hyperplasia (BPH) and Other Genitourinary Conditions medical policy:

  • Changed coverage decision for prostatic urethral lift from investigational and not medically necessary for the treatment of benign prostatic hyperplasia to medically necessary in members with prostate volume less than 80 mL and image-confirmed absence of an obstructing middle lobe as an alternative to open prostatectomy or transurethral resection of the prostate for the treatment of benign prostatic hyperplasia,
  • Added prostatic urethral lift as an investigational and not medically necessary procedure for all genitourinary conditions other than benign prostatic hyperplasia,
  • Revised investigational and not medically necessary procedure of prostatic urethral lift to specify that it is investigational and not medically necessary when criteria are not met.
  • Added the following medically necessary ICD-10 code:
    • 0-N40.3 – Benign prostatic hyperplasia
  • Changed the following CPT codes from investigational and not medically necessary to medically necessary:
    • 52441 – Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant
    • 52442 – Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; each additional permanent adjustable transprostatic implant
  • Changed the following HCPCS codes from investigational and not medically necessary to medically necessary:
    • C9739 – Cystourethroscopy, with insertion of transprostatic implant; 1 to 3 implants
    • C9740 – Cystourethroscopy, with insertion of transprostatic implant; 4 or more implants
  • Removed the following investigational and not medically necessary HCPCS code (deleted 12/31/2018):
    • C9748 – Transurethral destruction of prostate tissue; by radiofrequency water vapor (steam) thermal therapy

Read the complete policy here.

Anthem/Empire BCBS

Anthem Blue Cross as well as Empire Blue Cross Blue Shield has updated its Prior Authorization criteria to include:

  • Updated criteria to add requirement for individual to be concomitantly receiving a gonadotropin-releasing hormone (GnRH) analog or has had a bilateral orchiectomy.
  • Updated definition of castration resistant disease progression.

Read the complete policy here.

Humana

Humana has revised its Brachytherapy medical policy with the following changes to limitations, coding and supporting information:

  • Added the following coverage limitation statements:
    • Humana members may not be eligible under the Plan for transperineal biodegradable material when utilized with brachytherapy;
    • Humana members may not be eligible under the Plan for 3D bioabsorbable tissue marker which are utilized to indicate the surgical boundaries after lumpectomy for radiation therapy
  • Added bladder cancer to indications for which Humana members may not be eligible for brachytherapy.
  • Added the following CPT code:
    • 55874 – Transperineal placement of biodegradable material, periprostatic, single or multiple injection(s), including image guidance, when performed (not covered if used to report any treatment outlined in the coverage limitations section)
  • Revised description, medical alternatives, definitions and references sections to reflect current research and standards.

Please click here and search “brachytherapy” to read the full policy.

United Healthcare

Effective October 1, 2019, Optum Health will start managing prior authorization requests for certain medical benefit injectable medications for United Healthcare commercial plan members. Optum Health is an affiliate company of United Healthcare. This includes the affiliate plans United Healthcare of Mid-Atlantic, Inc., Neighborhood Health Partnership and United Healthcare of the River Valley. Providers are asked to continue to request notification/prior authorization for United Healthcare Oxford, UMR, United Healthcare Community Plan and United Healthcare Medicare Advantage members through the existing processes until future notice. Providers will need to use a new process to request a prior authorization once the existing authorization expires or if there is a change in therapy. Changes in therapy include place of therapy, dose or frequency of administration. Active prior authorizations that were obtained through the current process will remain in place. The new process is designed to reduce the turnaround time for a determination. The system will document clinical requirements during the intake process and prompt providers to provide responses to the clinical criteria questions.

Read the complete update here.

Effective August 1, 2019, United Healthcare is changing the name of a reimbursement policy that applies to United Healthcare Medicare Advantage and United Healthcare Community Plan “Evaluation and Management (E/M) Policy, Professional” to align with the Centers for Medicare & Medicaid Services (CMS). The new policy name will be M&R Observation and Discharge Policy, Professional.

This policy also will be changed to address reimbursement for discharge codes 99238 and 99239. According to CMS guidelines, “The E/M discharge day management visit shall be reported for the date of the actual visit by the physician or qualified non-physician practitioner even if the patient is discharged from the facility on a different calendar date. Only one hospital discharge day management service is payable per patient per hospital stay.” To be consistent with CMS guidelines, we are updating our policy to allow only one hospital discharge day management service per patient per hospital stay regardless of tax ID number. This policy change applies to services reported using the CMS-1500 paper form, its successor form or the CMS-1500 form electronic equivalent.

Read the complete update here.

United Healthcare will require Prior Authorization for the following therapeutic radiopharmaceuticals:

  • Lutetium Lu 177 (Lutathera®)
  • Radium RA-233 dichloride (Xofigo®)

All therapeutic radiopharmaceuticals that have not yet received an assigned code and will be billed under a miscellaneous HCPCS code Therapeutic radiopharmaceuticals billed under the following HCPCS codes require prior authorization:

  • A9513 Lutetium Lu 177, dotatate, therapeutic, 1 mCi
  • A9606 Radium RA-223 dichloride, therapeutic, per microcurie
  • A9699 Radiopharmaceutical, therapeutic, not otherwise classified

If a member receives injectable chemotherapy drugs, or related cancer therapies in an outpatient setting between July 1, 2019 and September 30, 2019, providers will not need to request prior authorization until administration of a new chemotherapy drug or related cancer therapy. United Healthcare will authorize the chemotherapy regimen the member was receiving prior to October 1, 2019. The authorization will be effective until September 30, 2020.

Read the complete update here.

United Healthcare has revised its Urological Supplies medical policy with the following changes:

  • Added guidelines for catheter insertion tray, urinary drainage collection system, continuous irrigation of indwelling catheters, intermittent irrigation of indwelling catheters, intermittent catheterization, and external catheters/urinary collection devices,
  • Added coverage statement for a specialty indwelling catheter or an all silicone catheter when the criteria for an indwelling catheter are met and there is documentation in the member’s medical record to justify the medical need for that catheter (such as recurrent encrustation, inability to pass a straight catheter, or sensitivity to latex),
  • Added coverage statement for a three-way indwelling catheter either alone or with other components if continuous catheter irrigation is reasonable and necessary,
  • Added coverage statement for supplies for continuous irrigation of a catheter if there is a history of obstruction of the catheter and the patency of the catheter cannot be maintained by intermittent irrigation in conjunction with reasonable and necessary catheter changes. Covered supplies for reasonable and necessary continuous bladder irrigation include a 3-way Foley catheter, irrigation tubing set, and sterile water/saline,
  • Added non-covered policy statement for irrigation solutions containing antibiotics and chemotherapeutic agents,
  • Added non-covered policy statement for irrigation supplies that are used for care of the skin or perineum of incontinent members,
  • Added coverage statement for supplies for the intermittent irrigation of an indwelling catheter when they are used on an as needed (non-routine) basis in the presence of acute obstruction of the catheter. Covered supplies for reasonable and necessary non-routine irrigation of a catheter include either an irrigation tray or an irrigation syringe, and sterile water/saline,
  • Added coverage criteria for intermittent catheterization using a sterile intermittent catheter to state that member must meet one of the following:
    • the member resides in a nursing facility; the member is immunosuppressed (for example, on a regimen of immunosuppressive drugs post-transplant, on cancer chemotherapy, has AIDS, or has a drug-induced state such as chronic oral corticosteroid use); the member has radiologically documented vesico-ureteral reflux while on a program of intermittent catheterization;
    • the member is a spinal cord injured female with neurogenic bladder who is pregnant (for duration of pregnancy only); or
    • the member has had distinct, recurrent urinary tract infections, while on a program of sterile intermittent catheterization and sterile lubricant, twice within the 12-month prior to the initiation of sterile intermittent catheter kits,
  • Added requirements for members to be considered to have a urinary tract infection, including a urine culture with greater than 10,000 colony forming units of a urinary pathogen and concurrent presence of one or more of the following signs, symptoms, or laboratory findings:
    • fever (oral temperature greater than 38º C [100.4º F]); systemic leukocytosis;
    • change in urinary urgency, frequency, or incontinence;
    • appearance of new or increase in autonomic dysreflexia (sweating, bradycardia, blood pressure elevation);
    • physical signs of prostatitis, epididymitis, orchitis;
    • increased muscle spasms; or
    • pyuria (greater than 5 white blood cells per high-powered field).
  • Added coverage statement for male external catheters (condom-type) or female external urinary collection devices for members who have permanent urinary incontinence when used as an alternative to an indwelling catheter,
  • Added coverage statement for specialty type male external catheters such as those that inflate or that include a faceplate or extended wear catheter systems when documentation substantiates the medical necessity for such a catheter,
  • Removed quantity limits for appliance cleaner, tape, adhesive catheter anchoring devices, and catheter leg straps in the miscellaneous supplies section,
  • Added the following modifiers:
    • AU – Item furnished in conjunction with a urological, ostomy, or tracheostomy supply
    • EY – No physician or other licensed health care provider order for this item or service
    • KX – Requirements specified in the medical policy have been met
  • Added the following instructions for using the AU modifier:
    • when codes A4217, A4450, and A4452 are used with urological supplies, they must be billed with the AU modifier. For this policy, codes A4217, A4450, and A4452 are the only three codes for which the AU modifier may be used,
  • Added the following instructions for using the KX modifier:
    • suppliers must add a KX modifier to a code for a catheter, an external urinary collection device, or a supply used with one of these items only if all of the criteria in the “Coverage Indications, Limitations and/or Medical Necessity” section of the related CMS Local Coverage Determination (LCD) have been met and evidence of such is maintained in the supplier’s files,
  • Updated description of the following HCPCS code:
    • A9270 – Non-covered item or service, including but not limited to the following items:
      • irrigation solutions containing antibiotics and chemotherapeutic agents,
      • catheter care kits,
      • catheter clamp or plug,
      • drainage bag holder or stand,
      • urinary suspensory without leg bag,
      • measuring container,
      • urinary drainage tray,
      • other incontinence products not directly related to the use of a covered urinary catheter or external urinary collection device (not covered by Medicare).

Read the complete policy here. 

Local and Regional Updates

The following are updates in your Section. Please contact AUA Executive Vice President Kathleen Zwarick at kzwarick@AUAnet.org for more information on any of these issues. A majority of state legislatures have adjourned for the remainder of 2019. Regardless, the AUA will continue to monitor state legislative, regulatory, and insurance issues that affect urology.

Delaware

Highmark Blue Cross Blue Shield update includes Delaware, Pennsylvania, and West Virginia.

Highmark Blue Cross Blue Shield has developed a new Reimbursement Policy for Telemedicine and Telehealth Services. This is to help establish the requirements for the current and future reimbursement direction of telemedicine services. Effective July 15, 2019, this policy will apply to both commercial and Medicare Advantage products.

Professional services rendered via an interactive telecommunication system are only eligible for reimbursement to the provider rendering the telehealth services. A provider rendering face-to-face care should report the appropriate codes for the in-person services.

When billing professional services (1500/837P), Virtual Primary Care Provider (PCP) Visits and Virtual Retail Clinic Visits should be billed with Evaluation & Management (E&M) CPT codes (99201-99205; 99211-99215) applicable to the services provided and with the GT or 95- modifier indicating the use of interactive audio and video telecommunications technology.

Outpatient facility claims (UB-04/837I) should be billed using the appropriate procedure code (99201- 99205; 99211-99215 or G0463) with the GT or 95 modifiers and the revenue code 780.

Place of Service “02” (Telehealth) must be used when reporting professional telehealth services (1500 form). OP Facility claims must also use the GT and 95 modifiers as appropriate and applicable.

The CPT Evaluation and Management code definitions are as follows:

  • 99201 – Office or other outpatient visit for the evaluation and management of a new patient, which requires these three key components: a problem focused history; a problem focused examination; and straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient’s and/or family’s needs. Usually, the presenting problem(s) are self-limited or minor. Typically, 10 minutes are spent face-to-face with the patient and/or family. Billing Instructions: Bill 1 unit per visit.
  • 99202 – Office or other outpatient visit for the evaluation and management of a new patient, which requires these three key components: an expanded problem focused history; an expanded problem focused examination; and straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient’s and/or family’s needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 20 minutes are spent face-to-face with the patient and/or family. Billing Instructions: Bill 1 unit per visit.
  • 99203 – Office or other outpatient visit for the evaluation and management of a new patient, which requires these three key components: a detailed history; a detailed examination; and medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient’s and/or family’s needs. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent face-to-face with the patient and/or family. Billing Instructions: Bill 1 unit per visit.
  • 99204 – Office or other outpatient visit for the evaluation and management of a new patient, which requires these three key components: a comprehensive history; a comprehensive examination; and medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient’s and/or family’s needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
    Billing Instructions: Bill 1 unit per visit.
  • 99205 – Office or other outpatient visit for the evaluation and management of a new patient, which requires these three key components: a comprehensive history; a comprehensive examination; and medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient’s and/or family’s needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent face-to-face with the patient and/or family. Billing Instructions: Bill 1 unit per visit.
  • 99212 – Requires at least 2 of these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient’s and/or family’s needs. Usually, the presenting problem(s) are self-limited or minor. Typically, 10 minutes are spent face-to-face with the patient and/or family.
  • 99213 – Requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient’s and/or family’s needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family. 
  • 99214 – Requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient’s and/or family’s needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
  • 99215 – Requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient’s and/or family’s needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family. 

Read the full policy here. 

Pennsylvania

AmeriHealth, an Independence Blue Cross company, has updated its Evaluation and Treatment of Erectile Dysfunction (ED) medical policy. They have made the following changes to the policy:  

  • Added a disclaimer indicating that the Company reserves the right to reimburse only those services that are furnished in the most appropriate and cost-effective setting that is appropriate to the member’s medical needs and condition.
  • Updated criteria regarding treatment of erectile dysfunction. For example, removed the criteria regarding vacuum constriction devices.
  • Added a section to indicate that vacuum constriction devices are not covered by the Company because they are items not covered by the Medicare.
  • Updated the policy guidelines section to indicate that this policy is consistent with Medicare’s coverage determination.
  • Added a section for ICD-10 diagnosis code numbers to include the following codes, which include, but are not limited to:
    • 21 – Male erectile disorder
    • 01 – Erectile dysfunction due to arterial insufficiency
    • 02 – Corporo-venous occlusive erectile dysfunction
    • 03 – Combined arterial insufficiency and corporo-venous occlusive erectile dysfunction
    • 1 – Erectile dysfunction due to diseases classified elsewhere
    • 2 – Drug-induced erectile dysfunction
    • 31 – Erectile dysfunction following radical prostatectomy
    • 32 – Erectile dysfunction following radical cystectomy
    • 33 – Erectile dysfunction following urethral surgery
    • 34 – Erectile dysfunction following simple prostatectomy

Read the complete policy here.

Maryland

The following Amerigroup coverage update includes Maryland, District of Columbia, and New Jersey.

Amerigroup has updated its pharmacy policy for Xtandi with the following changes:

  • Updated criteria to add requirement for individual to be concomitantly receiving a gonadotropin-releasing hormone (GnRH) analog or has had a bilateral orchiectomy.

Read the complete policy here. 

ICYMI: Updates from the AUA Policy & Advocacy Brief blog

Patient Advocacy: Coalition Meets with More than 120 Congressional Offices to Support Research Funding
On July 17-18, the AUA participated in the seventh annual We Work For Health Advocacy Summit in Washington, DC. The purpose of the event was to elevate awareness about legislative issues impacting healthcare innovation and patient access to treatment and care. The meeting brought together more than 140 advocates from 20 states to strategize about ways to promote research and innovation that improves patient quality of life.

Coalition advocates, who work on behalf of patients, physicians, and the biopharmaceutical industry, met with more than 120 legislative offices throughout the event. The AUA participated in meetings with offices of the Maryland delegation including Senators Chris Van Hollen (D-MD) and Ben Cardin (D-MD), and Representatives Andy Harris (R-MD-1), John Sarbanes (D-MD-3), Anthony Brown (D-MD-4), and Steny Hoyer (D-MD-5), and Jamie Raskin (D-MD-8). Read more here.

Medicare Drug Pricing Legislation: AUA Signs Alliance of Specialty Medicine (ASM) Letter

On July 25, the AUA agreed to sign a letter, with its partners from the ASM, on the recently proposed bipartisan Prescription Drug Pricing Reduction Act (PDPRA). Introduced by Chairman Chuck Grassley (R-IA) and Ranking Member Ron Wyden (D-OR) of the Senate Finance Committee, the proposal is intended to increase transparency into pharmacy benefit manager practices and manufacturer drug pricing decisions, improve how Medicare calculates Part B prescription drug payment amounts in an effort to lower spending and beneficiary out-of-pocket costs, and eliminate excess Part B drug payments that drive up beneficiary and program costs, among other things.

The letter expresses concern for the measure’s requirement to include the value of manufacturer drug coupons in Average Sales Price (ASP) reporting. This provision could result in further cuts to physicians that administer drugs in their offices, increase the gap between what small and rural practices pay to acquire the drugs for their patients and what they are reimbursed by Medicare, and possibly decrease access for many patients to certain drugs and medications. Read more here.

Your Help is Needed: Take the Advocacy Survey!

On July 29, an email went out from the AUA’s Public Policy Chair, Dr. Chris Gonzalez, asking for help in identifying relationships that AUA members have with their local and federally elected officials and gauging his/her overall interest in advocacy on behalf of the urologic specialty. The questionnaire should take no more than 10 minutes, and can be found by clicking here. As the AUA continues to advance its advocacy efforts, it is vital that we identify urologists that treat, go to church, synagogue, or other religious services with, or have a child in school programs with, etc., elected officials that may affect health policy at the local, state, and federal level.

If you have any questions or issues with the questionnaire, please contact AUA Legislative & Political Affairs manager Josh Webster at JWebster@AUAnet.org.

2020 Gallagher Scholar: AUA Accepting Applications

The AUA is now accepting applications for the 2020 Gallagher Health Policy Scholar program. Applicants must be AUA member urologists who have demonstrated a commitment to or have a keen interest in the field of health policy and who are dedicated to advancing urology’s health policy agenda. Previous Gallagher Scholars are now among some of the AUA’s top health policy leaders, and attribute participation in this program as a key step in making the transition into leadership roles. Learn more about the program and how to apply.